Focusing on NSCLC, in a distinct retrospective monocentric study of 74 patients with RET fusion + NSCLC, the authors reported that most of the evaluable patients (81%, 21/26) were PD-L1 negative (58%, 15/26) or intermediate (<50%) (23%, 6/26), and among the 44 patients with sufficient tumor sample for TMB, the mTMB was significantly lower in respect to that of 3631 RET wild-type NSCLC patients (1.75 vs. 5.27 mutations/Mb) [38]. This evidence concerns the gene RET and neoplasm.